Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Unifying rare diseases may enable multiple treatments

May 9, 2019

First clinical data of an ARSB gene therapy for mucopolysaccharidosis type VI

May 9, 2019

Lentiviral CYBB gene therapy relieves disease symptoms in an X-CGD infant

May 8, 2019

Waylivra receives conditional marketing authorization from the European Commission

May 8, 2019

European Commission approves Palynziq to treat PKU

May 7, 2019

Qternmet XR approved in U.S. for type 2 diabetes

May 3, 2019

Dietary supplement increases brown fat activity

April 30, 2019

ObsEva reports follow-up data from phase III IMPLANT2 study of nolasiban

April 29, 2019

European Commission approves Zynquista for type 1 diabetes

April 29, 2019

Novo Nordisk reports phase III results with Victoza in pediatric type 2 diabetes

April 29, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...